US6652882B1
(en)
*
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US7098206B2
(en)
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
WO1999038504A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
EP1051166A1
(en)
*
|
1998-01-29 |
2000-11-15 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (+) -bupropion
|
AU2349999A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmacological uses of pure (+) -bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
EP1093348A4
(en)
*
|
1998-06-29 |
2003-07-16 |
Pharmaceuticals Applic Asociat |
TRANSDERMAL ANALGESIC COMPOSITIONS AND METHODS OF ADMINISTRATION
|
US6238697B1
(en)
*
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6855820B2
(en)
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6312716B1
(en)
*
|
1999-05-10 |
2001-11-06 |
Peierce Management Llc |
Patch and method for transdermal delivery of bupropion base
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
EP1284729A4
(en)
*
|
2000-04-13 |
2007-12-19 |
Mayo Foundation |
REDUCTION AGENTS OF A (BETA) 42
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
US6333332B1
(en)
*
|
2000-08-25 |
2001-12-25 |
Impax Laboratories, Inc. |
Stabilized pharmaceutical compositions containing bupropion hydrochloride
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
JP4625637B2
(ja)
|
2002-02-22 |
2011-02-02 |
シャイア エルエルシー |
活性物質送達系及び活性物質を保護し投与する方法
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
CN1320886C
(zh)
*
|
2002-05-17 |
2007-06-13 |
杜克大学 |
安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
US20040191298A1
(en)
*
|
2003-03-26 |
2004-09-30 |
Fredrik Nicklasson |
New formulations and use thereof
|
PL2316456T3
(pl)
*
|
2003-04-29 |
2017-12-29 |
Orexigen Therapeutics, Inc. |
Kompozycje wpływające na utratę masy zawierające antagonistę opioidów i bupropion
|
EP1651195A4
(en)
*
|
2003-07-11 |
2007-10-03 |
Myriad Genetics Inc |
PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
AU2005206139B2
(en)
|
2004-01-13 |
2009-02-26 |
Duke University |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
US20060100205A1
(en)
*
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
AU2005241023A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US8586085B2
(en)
*
|
2004-11-08 |
2013-11-19 |
Biokey, Inc. |
Methods and formulations for making pharmaceutical compositions containing bupropion
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
KR100670798B1
(ko)
|
2004-12-17 |
2007-01-17 |
한국전자통신연구원 |
데이터베이스 캐시 시스템
|
US20060204571A1
(en)
*
|
2005-03-12 |
2006-09-14 |
Sun Pharmaceutical Industries Limited |
Stable compositions of bupropion or its pharmaceutically acceptable salts
|
JP5095615B2
(ja)
*
|
2005-06-27 |
2012-12-12 |
バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ |
ブプロピオン塩の放出調整製剤
|
EA200800360A1
(ru)
*
|
2005-07-22 |
2008-06-30 |
Мириад Дженетикс, Инк. |
Формуляции с высоким содержанием лекарства и дозированные формы
|
CN101374507A
(zh)
*
|
2005-10-14 |
2009-02-25 |
H.隆德贝克有限公司 |
含有依他普仑和安非他酮的稳定药物制剂
|
EA200801081A1
(ru)
*
|
2005-10-14 |
2008-10-30 |
Х. Лундбекк А/С |
Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
|
DK2135603T3
(da)
|
2005-11-22 |
2013-03-25 |
Orexigen Therapeutics Inc |
Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
|
ES2383330T3
(es)
*
|
2005-11-28 |
2012-06-20 |
Orexigen Therapeutics, Inc. |
Formulación de liberación sostenida de zonisamida
|
EP1999303A4
(en)
*
|
2006-02-27 |
2010-09-08 |
Univ Leland Stanford Junior |
METHODS FOR IDENTIFYING RESPONSE INHIBITORS TO DEPLOYED PROTEINS
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
CA2655139A1
(en)
|
2006-06-13 |
2008-04-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Epoxide inhibitors of cysteine proteases
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
KR100843021B1
(ko)
*
|
2006-09-11 |
2008-07-01 |
주식회사 드림파마 |
안정성이 개선된 디에틸프로피온 하이드로클로라이드를포함하는 경구투여용 고형 제제
|
US8088786B2
(en)
|
2006-11-09 |
2012-01-03 |
Orexigen Therapeutics, Inc. |
Layered pharmaceutical formulations
|
WO2008060964A2
(en)
*
|
2006-11-09 |
2008-05-22 |
Orexigen Therapeutics, Inc. |
Unit dosage package and methods for administering weight loss medications
|
EP2142183A2
(en)
|
2007-04-09 |
2010-01-13 |
Sepracor Inc. |
Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
|
WO2009111031A2
(en)
*
|
2008-03-04 |
2009-09-11 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
US20110144145A1
(en)
*
|
2008-05-30 |
2011-06-16 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US9248123B2
(en)
|
2010-01-11 |
2016-02-02 |
Orexigen Therapeutics, Inc. |
Methods of providing weight loss therapy in patients with major depression
|
CA2814503A1
(en)
|
2010-10-11 |
2012-04-19 |
The Board Of Trustees Of The Leland Stanford Junior Unversity |
Substituted benzamides and their uses
|
KR101534606B1
(ko)
*
|
2011-11-08 |
2015-07-10 |
알보젠코리아 주식회사 |
사포그릴레이트의 안정화된 지속 방출 제제
|
JP6031527B2
(ja)
|
2011-11-21 |
2016-11-24 |
キャリセラ バイオサイエンシーズ, インコーポレイテッド |
グルタミナーゼのヘテロ環式阻害剤
|
SG10201509063SA
(en)
|
2012-04-12 |
2015-12-30 |
Univ Leland Stanford Junior |
Substituted benzamides and their uses
|
ES2802048T3
(es)
|
2012-06-06 |
2021-01-15 |
Nalpropion Pharmaceuticals Llc |
Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
|
WO2014078645A1
(en)
|
2012-11-16 |
2014-05-22 |
Calithera Biosciences, Inc. |
Heterocyclic glutaminase inhibitors
|
KR102279618B1
(ko)
|
2013-03-15 |
2021-07-20 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
활성 기반 프로브 화합물, 조성물, 및 사용 방법
|
US11324670B2
(en)
*
|
2013-10-16 |
2022-05-10 |
Bilal Walk |
Cocoa butter powdered moisturizer
|
US11969421B2
(en)
|
2013-11-05 |
2024-04-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
SG11201610333VA
(en)
|
2014-06-13 |
2017-01-27 |
Calithera Biosciences Inc |
Combination therapy with glutaminase inhibitors
|
MX2017001620A
(es)
|
2014-08-07 |
2017-05-10 |
Calithera Biosciences Inc |
Formas cristalinas de inhibidores de glutaminasa.
|
UY36272A
(es)
|
2014-08-13 |
2016-02-29 |
Eolas Therapeutics Inc |
Difluoropirrolidinas como moduladores de los receptores de orexinas
|
EP3212195A4
(en)
|
2014-10-31 |
2018-06-06 |
The Regents of The University of California |
Compositions and methods for treating hiv-associated cognitive dysfunction
|
KR101612197B1
(ko)
*
|
2014-11-25 |
2016-04-14 |
알보젠코리아 주식회사 |
부프로피온 염산염을 함유하는 안정화된 정제 및 이의 제조방법
|
EP4023645A1
(en)
|
2015-03-10 |
2022-07-06 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
AU2016281620B2
(en)
|
2015-06-23 |
2021-07-22 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
EP3359150A4
(en)
|
2015-10-05 |
2019-11-06 |
Calithera Biosciences, Inc. |
COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
|
RS60695B1
(sr)
|
2015-10-30 |
2020-09-30 |
Calithera Biosciences Inc |
Supstance i postupci za inhibiranje aktivnosti arginaze
|
BR112018009946A8
(pt)
|
2015-11-16 |
2019-02-26 |
Ichorion Therapeutics Inc |
pró-fármacos de ácido nucleico
|
EA036542B9
(ru)
|
2016-02-12 |
2020-12-22 |
Астразенека Аб |
Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора
|
US10793590B2
(en)
|
2016-06-03 |
2020-10-06 |
President And Fellows Of Harvard College |
Antifungal compounds
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
EP3509583B1
(en)
|
2016-09-09 |
2021-06-30 |
The Regents of the University of California |
Estrogen receptor ligands, compositions and methods related thereto
|
EP3510040A4
(en)
|
2016-09-09 |
2020-06-03 |
Calithera Biosciences, Inc. |
ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE
|
AU2017330443B2
(en)
|
2016-09-26 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Chromobox protein inhibitors and uses thereof
|
RS64399B1
(sr)
|
2016-09-28 |
2023-08-31 |
Medicon Pharmaceuticals Inc |
Kompozicije za lečenje oftalmoloških stanja
|
WO2018064354A1
(en)
|
2016-09-28 |
2018-04-05 |
Medicon Pharmaceuticals, Inc. |
Compositions and methods for treating ophthalmic conditions
|
MA46793A
(fr)
|
2016-11-08 |
2019-09-18 |
Calithera Biosciences Inc |
Polythérapies faisant appel à un inhibiteur d'arginase
|
US10287303B2
(en)
|
2016-12-22 |
2019-05-14 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
CA3033092C
(en)
|
2016-12-23 |
2023-12-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Activity-based probe compounds, compositions, and methods of use
|
BR112019014759A2
(pt)
|
2017-01-18 |
2020-03-03 |
Vanderbilt University |
Compostos heterocíclicos fundidos como inibidores seletivos de bmp
|
BR112019017567A2
(pt)
|
2017-02-24 |
2020-03-24 |
Merck Patent Gmbh |
Derivados de 1,4,6-trissubstituído-2-alquil-1h-benzo[d]imidazol como inibidores da di-hidro-orotato oxigenase
|
RS64411B1
(sr)
|
2017-03-31 |
2023-09-29 |
Aurigene Oncology Ltd |
Jedinjenja i kompozicije za lečenje hematoloških poremećaja
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
US11325943B2
(en)
|
2017-06-02 |
2022-05-10 |
Stealth Biotherapeutics Inc. |
Crystalline salt forms of SBT-20
|
WO2019018539A1
(en)
|
2017-07-19 |
2019-01-24 |
California Institute Of Technology |
PROCESSES FOR PREPARING COMPOUNDS CONTAINING BIS-TETRAHYDROISOQUINOLINE
|
EA202090536A1
(ru)
|
2017-10-11 |
2020-07-22 |
Ориджен Дискавери Текнолоджис Лимитед |
Кристаллические формы 3-замещенного 1,2,4-оксадиазола
|
FI3704108T3
(fi)
|
2017-10-31 |
2024-05-23 |
Curis Inc |
Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon
|
EA202090746A1
(ru)
|
2017-11-03 |
2020-08-17 |
Ориджен Дискавери Текнолоджис Лимитед |
Двойные ингибиторы путей tim-3 и pd-1
|
AU2018360389A1
(en)
|
2017-11-06 |
2020-05-07 |
Aurigene Oncology Limited |
Conjoint therapies for immunomodulation
|
CA3085097A1
(en)
|
2017-12-22 |
2019-06-27 |
Medimmune Limited |
Small molecule modulators of the btb domain of keap1
|
EP3765460A1
(en)
|
2018-03-14 |
2021-01-20 |
Vanderbilt University |
Inhibition of bmp signaling, compounds, compositions and uses thereof
|
EP3773614A1
(en)
|
2018-04-12 |
2021-02-17 |
Matrx Therapeutics Corporation |
Compositions and methods for treating elastic fiber breakdown
|
US11155638B2
(en)
|
2018-05-08 |
2021-10-26 |
Rhode Island Hospital |
Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
|
US20210122771A1
(en)
|
2018-06-29 |
2021-04-29 |
The Regents Of The University Of California |
New molecular tweezers against neurological disorders and viral infections
|
KR20210062626A
(ko)
|
2018-07-27 |
2021-05-31 |
캘리포니아 인스티튜트 오브 테크놀로지 |
Cdk 억제제 및 이의 용도
|
US20220218652A1
(en)
|
2018-09-05 |
2022-07-14 |
The General Hospital Corporation |
Methods of treating cytokine release syndrome
|
CN114269345A
(zh)
|
2018-10-26 |
2022-04-01 |
科乐斯疗法公司 |
Alk2抑制剂的晶体形式
|
MX2021008533A
(es)
|
2019-01-18 |
2021-08-19 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y metodos de uso de los mismos.
|
KR20210137434A
(ko)
|
2019-01-25 |
2021-11-17 |
브라운 유니버시티 |
연령 관련 염증 및 장애를 치료, 예방 또는 역전시키기 위한 조성물 및 방법
|
AU2020214626A1
(en)
|
2019-01-31 |
2021-09-16 |
Elektrofi, Inc. |
Particle formation and morphology
|
CN113573709A
(zh)
|
2019-03-14 |
2021-10-29 |
阿斯利康(瑞典)有限公司 |
用于体重减轻的兰比斯特
|
JP6890865B1
(ja)
|
2019-06-03 |
2021-06-18 |
株式会社大分大学先端医学研究所 |
狂犬病治療のための環状アミド化合物およびその方法
|
CN110200947A
(zh)
*
|
2019-06-27 |
2019-09-06 |
深圳市泛谷药业股份有限公司 |
一种安非他酮肠溶缓释微丸胶囊及其制备方法
|
JP2022547546A
(ja)
|
2019-09-13 |
2022-11-14 |
エレクトロフィ,インコーポレイテッド |
疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
|
CN114981243A
(zh)
|
2019-11-12 |
2022-08-30 |
健赞公司 |
用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
EP4079309A4
(en)
|
2019-12-16 |
2024-01-10 |
Ulsan National Institute Of Science And Tech Unist |
COMPOUND FOR INHIBITING ANGIOGENESIS FACTOR AND USE THEREOF
|
WO2021158959A2
(en)
|
2020-02-07 |
2021-08-12 |
Elektrofi, Inc. |
Peptide particles and methods of formation
|
US20230065628A1
(en)
|
2020-02-19 |
2023-03-02 |
Elektrofi, Inc. |
Droplet Formation and Particle Morphology
|
CN115484934A
(zh)
|
2020-04-17 |
2022-12-16 |
伊勒卓菲公司 |
通过连续液滴形成和脱水形成颗粒的方法
|
WO2021263072A1
(en)
|
2020-06-25 |
2021-12-30 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating disease
|
AU2021325872A1
(en)
|
2020-08-10 |
2023-03-16 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
US20230271918A1
(en)
|
2020-08-10 |
2023-08-31 |
Dana-Farber Cancer Institute, Inc. |
Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
|
AU2021326457A1
(en)
|
2020-08-10 |
2023-03-16 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
WO2022087433A1
(en)
|
2020-10-23 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
|
AU2021390502A1
(en)
|
2020-12-01 |
2023-06-22 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for reduction of suicide risk in depression patients
|
WO2022133237A2
(en)
|
2020-12-18 |
2022-06-23 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
JP2024504512A
(ja)
|
2020-12-21 |
2024-01-31 |
コーネル・ユニバーシティー |
ペプチド連結薬物送達系
|
US20240132480A1
(en)
|
2021-01-08 |
2024-04-25 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
US20220363696A1
(en)
|
2021-04-13 |
2022-11-17 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
CA3230259A1
(en)
|
2021-09-03 |
2023-03-09 |
Junkai Liao |
Indole compounds and methods of use
|
AU2022357554A1
(en)
|
2021-10-01 |
2024-04-11 |
Nuvalent, Inc. |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
WO2023056431A1
(en)
|
2021-10-01 |
2023-04-06 |
Nuvalent, Inc. |
Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
|
WO2023187422A1
(en)
|
2022-03-31 |
2023-10-05 |
Revolo Biotherapeutics Limited |
Compositions and their use in methods for treating intestinal inflammation
|
WO2023196910A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc |
Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
|
WO2023196900A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc. |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
WO2023212721A1
(en)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Injectable suspensions
|
WO2023223015A1
(en)
|
2022-05-16 |
2023-11-23 |
Revolo Biotherapeutics Limited |
Methods and compositions for preventing or treating food allergies
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
US11717518B1
(en)
|
2022-06-30 |
2023-08-08 |
Antecip Bioventures Ii Llc |
Bupropion dosage forms with reduced food and alcohol dosing effects
|
WO2024006812A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising bupropion and cysteine
|
WO2024006853A1
(en)
|
2022-06-30 |
2024-01-04 |
Antecip Bioventures Ii Llc |
Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
|
US11730706B1
(en)
|
2022-07-07 |
2023-08-22 |
Antecip Bioventures Ii Llc |
Treatment of depression in certain patient populations
|
US11844797B1
(en)
|
2023-04-20 |
2023-12-19 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
WO2024013209A1
(en)
|
2022-07-13 |
2024-01-18 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
WO2024036097A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds and isotopologues thereof
|
WO2024036098A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds
|
WO2024086634A1
(en)
|
2022-10-19 |
2024-04-25 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|